» Articles » PMID: 35907101

Inborn Errors of Immunity in Patients with Adverse Events Following BCG Vaccination in Brazil

Overview
Journal J Clin Immunol
Publisher Springer
Date 2022 Jul 30
PMID 35907101
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The Bacille Calmette-Guérin (BCG) vaccine is routinely applied in Brazil. Adverse events (AE) may occur in patients with inborn or acquired immunodeficiencies, varying between local (BCGitis) or disseminated (BCGosis) reactions. We evaluated 53 individuals with local or disseminated adverse events to BCG vaccination to assess if they had inborn errors of immunity (IEI).

Methods: Patients diagnosed with an adverse event following BCG vaccination between 2014 and 2017 were included in the study. We collected clinical data, immunophenotyped T and B lymphocytes, and natural killer cells (NK), assessed oxidative function of neutrophils through dihydrorhodamine (DHR) 123 testing, and genotyped 361 genes related to IEI through targeted (panel) sequencing.

Results: The median age of the 53 individuals was four months (IQ 1.5-12), and 52.8% were male. Forty-eight (90.6%) individuals presented only locoregional AE and five (9.4%) presented both locoregional and disseminated AE. Nine (16.9%) patients were diagnosed with an IEI. Four of them presented BCGitis and five presented BCGosis after BCG vaccination. Clinically, four presented chronic granulomatous disease (CGD), three Mendelian susceptibility to mycobacterial disease (MSMD), and two severe combined immunodeficiency (SCID). Patients with IEI had a higher frequency of systemic symptomatology (p = 0.002), history of other infections (p < 0.001), parental consanguinity (p = 0.01), familial history of sick siblings (p < 0.001), or early deaths in the family (p < 0.01).

Conclusion: There is a high frequency of IEI in patients with locoregional and disseminated adverse events to BCG vaccination, revealing the need for the investigation of IEI accompanied by clinical and familial inquiry.

Citing Articles

Fatal viscerotropic and neurotropic disease after yellow fever vaccine: a rare manifestation leading to diagnosis of severe combined immunodeficiency in an infant.

Vieira L, Goebel G, Barcelos Y, Cunha L, Santos L, Romanelli R Rev Inst Med Trop Sao Paulo. 2024; 66:e50.

PMID: 39194142 PMC: 11348792. DOI: 10.1590/S1678-9946202466050.


Diagnosis and Management of Infections in Patients with Mendelian Susceptibility to Mycobacterial Disease.

Dalvi A, Bargir U, Natraj G, Shah I, Madkaikar M Pathogens. 2024; 13(3).

PMID: 38535546 PMC: 10975294. DOI: 10.3390/pathogens13030203.

References
1.
World Health Organization . BCG vaccine: WHO position paper, February 2018 - Recommendations. Vaccine. 2018; 36(24):3408-3410. DOI: 10.1016/j.vaccine.2018.03.009. View

2.
Boman G . The ongoing story of the Bacille Calmette-Guérin (BCG) vaccination. Acta Paediatr. 2016; 105(12):1417-1420. DOI: 10.1111/apa.13585. View

3.
Moreira T, de Moraes-Pinto M, Costa-Carvalho B, Grumach A, Weckx L . CLINICAL MANAGEMENT OF LOCALIZED BCG ADVERSE EVENTS IN CHILDREN. Rev Inst Med Trop Sao Paulo. 2016; 58:84. PMC: 5096638. DOI: 10.1590/S1678-9946201658084. View

4.
Alrabiaah A, Alsubaie S, Bukhari E, Gad A, Alzamel F . Outbreak of Bacille Calmette-Guérin-related lymphadenitis in Saudi children at a university hospital after a change in the strain of vaccine. Ann Saudi Med. 2011; 32(1):4-8. PMC: 6087637. DOI: 10.5144/0256-4947.2012.4. View

5.
Bukhari E, Alzahrani M, Alsubaie S, Alrabiaah A, Alzamil F . Bacillus Calmette-Guerin lymphadenitis: a 6-year experience in two Saudi hospitals. Indian J Pathol Microbiol. 2012; 55(2):202-5. DOI: 10.4103/0377-4929.97869. View